Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 9/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31257047 | 0.93 | MME (0.43) | MMEACECPA1ACE2CTSD | |
| SCHEMBL29448562 | 0.89 | MME (0.46) | MMEACECPA1ACE2CTSD | |
| SCHEMBL34464920 | 0.89 | OPRD1 (0.38) | MMEACECPA1ACE2CTSD | |
| SCHEMBL29387536 | 0.87 | MME (0.43) | MMEACECPA1ACE2CTSD | |
| SCHEMBL29926236 | 0.86 | MME (0.50) | MMEACECPA1ACE2CTSD | |
| SCHEMBL29551119 | 0.85 | DPP4 (0.38) | MMECTSD | |
| SCHEMBL30051101 | 0.84 | ALDH1A1 (0.47) | MMEACECPA1ACE2ENPEP | |
| SCHEMBL30051636 | 0.84 | MME (0.53) | MMEACECPA1ACE2ENPEP | |
| SCHEMBL29445234 | 0.83 | BACE1 (0.40) | MMEACECPA1ACE2CTSD | |
| SCHEMBL31129093 | 0.82 | NPSR1 (0.38) | MMECTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | MME 2046/4885ACE 747/4885CPA1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.